CHRS Coherus BioSciences Inc.

Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th

Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th

REDWOOD CITY, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after market close on Monday, November 8, 2021. Starting at 5 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

After releasing third quarter financial results, the Company will post them on the Coherus website at .

Conference Call Information

When: Monday, Nov. 8, 2021, starting at 5 p.m. ET

Dial -in: (844) 452-6826 (Toll-Free U.S. and Canada) or (765) 507-2587 (International)

Conference ID: 1838568

Webcast: 

Please dial-in 15 minutes early to ensure a timely connection to the call.

About Coherus BioSciences

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. For additional information, please visit .

Coherus Contact Information:

Cheston Turbyfill

Coherus BioSciences, Inc.



EN
29/10/2021

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data fo...

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody – CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a >50% increase in intratumoral CD8 T cells – turning tumors “hot” REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced new multiomic tumor an...

November 7, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Reports Third Quarter 2025 Financial Results and Prov...

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update – CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 an...

November 6, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Aff...

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer – Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood’s responsibilities include key externally facing and strategic functions. “We are thrilled to have a such a well-regarded senior biotechnology executive j...

November 6, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Report Third Quarter 2025 Financial Results on Nov...

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of the live conference call. Con...

October 30, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific TimeJefferies Global Healthcare Conference in London, England on Tuesday, November 18, 2025, at 10:30 a.m. Greenwich Mean Time / 5:30 a.m. Eastern TimeBaird Biotech Discovery Series takes pl...

October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch